Table 1

Baseline demographic and disease characteristics of the patientsa
Not maintained DAS28 (ESR) <2.6 for 24 weeks (n = 146) Maintained DAS28 (ESR) <2.6 for 24 weeks (n = 69)
Discontinued ADA (n = 51) Pb Continued ADA (control) (n = 18) Pc
Age, year 61.1 ± 11.6 59.5 ± 11.2 0.3910 64.8 ± 10.4 0.0513
Gender, F:M 127:19 40:11 0.1742 14:4 1.0000
Disease duration, year 9.4 ± 10.3 7.1 ± 9.9 0.0356 6.7 ± 10.1 0.7375
RF, U/mL 137.2 ± 248.5 109.0 ± 143.0 0.5539 283.5 ± 550.5 0.1400
TJC, 0 to 28 8.9 ± 6.7 8.1 ± 6.6 0.4014 7.6 ± 5.4 0.9727
SJC, 0 to 28 7.5 ± 5.5 6.4 ± 5.0 0.1770 6.7 ± 4.5 0.6214
PGA, 0 to 100 mm 53.4 ± 24.8 39.0 ± 24.2 0.0008 47.8 ± 24.7 0.2185
EGA, 0 to 100 mm 39.6 ± 22.7d 31.5 ± 21.3 0.0398 34.7 ± 19.6g 0.4636
CRP, mg/dl 2.89 ± 4.07 2.27 ± 3.71 0.1460 1.61 ± 1.58 0.3817
ESR, mm/hour 51.9 ± 32.4 43.2 ± 33.6 0.0574 45.6 ± 25.0 0.4318
DAS28 (ESR) 5.57 ± 1.27 5.06 ± 1.26 0.0183 5.33 ± 1.25 0.3528
MMP-3, ng/ml 313 ± 363 217 ± 339 0.0301 333 ± 233 0.0005
HAQ, 0 to 3 1.37 ± 0.77e 0.91 ± 0.67 0.0003 1.27 ± 0.51h 0.0295
MTX, mg/wf 8.85 ± 3.11 8.96 ± 2.72 0.8937 9.61 ± 1.97 0.3480

aExcept where indicated otherwise, values are the mean ± SD; bnot maintained DAS28 (ESR) <2.6 for 24 weeks versus maintained DAS28 (ESR) <2.6 for 24 weeks/Discontinued ADA; cmaintained DAS28 (ESR) <2.6 for 24 weeks/Discontinued ADA versus maintained DAS28 (ESR) <2.6 for 24 weeks/Continued ADA (control); dN = 72; eN = 143; fthe mean ± SD were determined including those without concomitant administration of MTX by handling as zero; gN = 10; hN = 16. CPR, C-reactive protein; DAS28, disease activity score; EGA, evaluator’s global assessment of disease activity; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, patient’s global assessment of disease activity; RF, rheumatoid factor; TJC; tender joint count; SJC, swollen joint count.

Hirata et al.

Hirata et al. Arthritis Research & Therapy 2013 15:R135   doi:10.1186/ar4315

Open Data